Akeso's ivonescimab outperforms AstraZeneca's Imfinzi in Phase 3 biliary tract cancer trial

Chinese firm Akeso reported that its immunotherapy drug ivonescimab, combined with chemotherapy, demonstrated superior efficacy compared to AstraZeneca's Imfinzi in a Phase 3 trial for biliary tract cancer. The results bolster the competitive profile of Chinese-developed biologics in global markets, following a significant licensing agreement with Summit Therapeutics.